| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Zheng Yang | |
| Qi-Zhu Tang | |||
| Hai-Han Liao | |||
| Huang-Jun Liu | |||
| P2860 | cites work | Activation of peroxisome proliferator-activated receptor-alpha and -gamma in auricular tissue from heart failure patients. | Q54640549 |
| Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis | Q71662466 | ||
| Global remodeling of the ventricular interstitium in idiopathic myocardial fibrosis and sudden cardiac death | Q81684448 | ||
| Puerarin prevents isoprenaline-induced myocardial fibrosis in mice by reduction of myocardial TGF-β1 expression | Q82482648 | ||
| Tenascin-x facilitates myocardial fibrosis and cardiac remodeling through transforming growth factor-β1 and peroxisome proliferator-activated receptor γ in alcoholic cardiomyopathy | Q83505281 | ||
| Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma | Q83611006 | ||
| L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression | Q85847529 | ||
| Response to letter regarding article, "atrial fibrosis and conduction slowing in the left atrial appendage of patients undergoing thoracoscopic surgical pulmonary vein isolation for atrial fibrillation" | Q85927518 | ||
| Inhibitory effects of spironolactone on myocardial fibrosis in spontaneously hypertensive rats | Q86083518 | ||
| Effect of peroxisome proliferator-activated receptor gamma agonist on heart of rabbits with acute myocardial ischemia/reperfusion injury | Q87253922 | ||
| Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats (PPAR γ) | Q87318174 | ||
| Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits | Q87845915 | ||
| Down-regulation of the expression of angiotensin II type 1 receptor in neonatal rat cardiac fibroblast by activation of PPARgamma signal pathway. | Q51772287 | ||
| Activation of peroxisome proliferator-activated receptor γ (PPARγ) through NF-κB/Brg1 and TGF-β1 pathways attenuates cardiac remodeling in pressure-overloaded rat hearts. | Q53632194 | ||
| Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2. | Q54274801 | ||
| Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models. | Q54404882 | ||
| Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation. | Q54475197 | ||
| Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury | Q43972557 | ||
| PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1. | Q44203460 | ||
| Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction | Q44243308 | ||
| A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes | Q44353731 | ||
| The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction | Q44472847 | ||
| Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension | Q44513157 | ||
| Up-regulation of peroxisome proliferator-activated receptor gamma in radiation-induced heart injury in rats | Q44793448 | ||
| Diabetes drugs tied to fractures in women | Q44968221 | ||
| Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats | Q45220355 | ||
| Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance | Q45255881 | ||
| Osthole regulates TGF-β1 and MMP-2/9 expressions via activation of PPARα/γ in cultured mouse cardiac fibroblasts stimulated with angiotensin II. | Q45817713 | ||
| Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. | Q46486937 | ||
| Effect of rosiglitazone on cardiac fibroblast proliferation, nitric oxide production and connective tissue growth factor expression induced by advanced glycation end-products | Q46670528 | ||
| Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure | Q46723268 | ||
| Up-regulation of PPARgamma in myocardial infarction | Q46830855 | ||
| Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan | Q46833898 | ||
| Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats | Q46882639 | ||
| PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats | Q46902316 | ||
| Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner | Q47388835 | ||
| Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis | Q48235274 | ||
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Cellular and molecular mechanisms of fibrosis | Q24648892 | ||
| Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review | Q26866784 | ||
| Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice. | Q27309112 | ||
| Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer | Q30476541 | ||
| PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism | Q33283063 | ||
| Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels. | Q33577634 | ||
| Whole grape intake impacts cardiac peroxisome proliferator-activated receptor and nuclear factor kappaB activity and cytokine expression in rats with diastolic dysfunction | Q34088823 | ||
| Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol | Q34149341 | ||
| Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications | Q34150487 | ||
| Peroxisome proliferator-activated receptors for hypertension | Q34179017 | ||
| Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation | Q34295008 | ||
| PPAR Gamma Expression Levels during Development of Heart Failure in Patients with Coronary Artery Disease after Coronary Artery Bypass-Grafting. | Q34412608 | ||
| Telomere biology in cardiovascular disease - role of insulin sensitivity in diabetic hearts | Q34467089 | ||
| Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. | Q34588710 | ||
| Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial | Q34660831 | ||
| The origin of fibroblasts and mechanism of cardiac fibrosis | Q34994036 | ||
| Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice | Q34997831 | ||
| Inhibition of TGF-β by a novel PPAR-γ agonist, chrysin, salvages β-receptor stimulated myocardial injury in rats through MAPKs-dependent mechanism | Q35177115 | ||
| New insights into insulin resistance in the diabetic heart | Q35243945 | ||
| Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 phosphorylation cascade | Q35287105 | ||
| Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome | Q35613936 | ||
| Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association | Q35615572 | ||
| Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease | Q35636191 | ||
| Muscle ring finger-3 protects against diabetic cardiomyopathy induced by a high fat diet. | Q35716907 | ||
| ERK/GSK3β/Snail signaling mediates radiation-induced alveolar epithelial-to-mesenchymal transition. | Q35783218 | ||
| Transforming growth factor-β inhibits myocardial PPARγ expression in pressure overload-induced cardiac fibrosis and remodeling in mice | Q35885246 | ||
| MuRF2 regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet | Q35920226 | ||
| Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone | Q35989215 | ||
| The cardiac fibroblast: therapeutic target in myocardial remodeling and failure | Q36094597 | ||
| Fibrosis, Connexin-43, and Conduction Abnormalities in the Brugada Syndrome. | Q36245208 | ||
| Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions | Q36261125 | ||
| Corepressors of agonist-bound nuclear receptors | Q36288161 | ||
| Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance | Q36321335 | ||
| Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community | Q36439679 | ||
| Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect | Q36491985 | ||
| Pioglitazone attenuates valvular calcification induced by hypercholesterolemia | Q36612212 | ||
| Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. | Q36674142 | ||
| Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts | Q36734442 | ||
| Reactivation of Snail genes in renal fibrosis and carcinomas: a process of reversed embryogenesis? | Q36765406 | ||
| Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful? | Q37201071 | ||
| Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice | Q37201578 | ||
| Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages | Q37395127 | ||
| Cardiac fibroblasts: at the heart of myocardial remodeling | Q37491524 | ||
| PPARs and adipocyte function. | Q37601619 | ||
| Snail as a potential target molecule in cardiac fibrosis: paracrine action of endothelial cells on fibroblasts through snail and CTGF axis | Q37636881 | ||
| Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion | Q37637606 | ||
| Telmisartan attenuates isoproterenol-induced cardiac remodeling in rats via regulation of cardiac adiponectin expression | Q37727413 | ||
| Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation | Q37764239 | ||
| Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits? | Q37961919 | ||
| PPAR agonists for the treatment of cardiovascular disease in patients with diabetes | Q37996437 | ||
| Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. | Q38422501 | ||
| Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery. | Q38527229 | ||
| Management of cardiac fibrosis in diabetic rats; the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) and calcium channel blockers (CCBs) | Q39766035 | ||
| PEDF and 34-mer inhibit angiogenesis in the heart by inducing tip cells apoptosis via up-regulating PPAR-γ to increase surface FasL. | Q40373354 | ||
| Simvastatin activates the PPARγ-dependent pathway to prevent left ventricular hypertrophy associated with inhibition of RhoA signaling | Q40581719 | ||
| PPAR-γ agonist attenuates inflammation in aortic aneurysm patients | Q40693751 | ||
| Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction | Q41843180 | ||
| Hepatocyte-derived Snail1 propagates liver fibrosis progression | Q41865587 | ||
| A pilot study of circulating PPAR-γ receptor protein in elderly patients with atrial fibrillation | Q41955585 | ||
| DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy | Q41990989 | ||
| Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats | Q42258153 | ||
| Reduction of isoprenaline-induced myocardial TGF-β1 expression and fibrosis in osthole-treated mice | Q42727456 | ||
| Cardiac fibrosis in diabetic rats: regulation and mechanism of activation of the PPARgamma signal pathway. | Q42728839 | ||
| Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity | Q42829351 | ||
| Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation | Q43046058 | ||
| Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring. | Q43071641 | ||
| Ameliorative role of rosiglitazone in hyperhomocysteinemia-induced experimental cardiac hypertrophy. | Q43115444 | ||
| Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth fac | Q43245112 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug discovery | Q1418791 |
| P304 | page(s) | 2198645 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | PPAR Research | Q15756406 |
| P1476 | title | Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis | |
| P478 | volume | 2016 |
| Q42700724 | 5-HT induces PPAR γ reduction and proliferation of pulmonary artery smooth muscle cells via modulating GSK-3β/β-catenin pathway |
| Q89304971 | Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide |
| Q93199229 | Effect of fish oil on circulating asymmetric dimethylarginine and adiponectin in overweight or obese patients with atrial fibrillation |
| Q49908591 | Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance. |
| Q47136571 | MicroRNA-130a, a Potential Antifibrotic Target in Cardiac Fibrosis |
| Q48247479 | PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia. |
| Q90324378 | PPARγ Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model |
| Q37694630 | Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts |
| Q37171547 | Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor δ (PPARδ): from bedside to bench |
| Q33717198 | Traditional Chinese Medication Qiliqiangxin Protects Against Cardiac Remodeling and Dysfunction in Spontaneously Hypertensive Rats |
Search more.